ANI Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $771.98 million
- Book Value:
- Revenue TTM:
- $283.08 million
- Operating Margin TTM:
- Gross Profit TTM:
- $117.43 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
ANI Pharmaceuticals Inc had its IPO on 2000-05-05 under the ticker symbol ANIP.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. ANI Pharmaceuticals Inc has a staff strength of 601 employees.
Shares of ANI Pharmaceuticals Inc opened at $39.66 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $38.81 - $39.8, and closed at $39.53.
This is a +0.51% increase from the previous day's closing price.
A total volume of 63,512 shares were traded at the close of the day’s session.
In the last one week, shares of ANI Pharmaceuticals Inc have increased by +1.99%.
ANI Pharmaceuticals Inc's Key Ratios
ANI Pharmaceuticals Inc has a market cap of $771.98 million, indicating a price to book ratio of 2.2109 and a price to sales ratio of 2.4194.
In the last 12-months ANI Pharmaceuticals Inc’s revenue was $283.08 million with a gross profit of $117.43 million and an EBITDA of $21.62 million. The EBITDA ratio measures ANI Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ANI Pharmaceuticals Inc’s operating margin was -12.77% while its return on assets stood at -3.74% with a return of equity of -25.67%.
In Q3, ANI Pharmaceuticals Inc’s quarterly earnings growth was a negative -89% while revenue growth was a positive 61%.
ANI Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-5.03 per share while it has a forward price to earnings multiple of 11.8624 and a PEG multiple of 1.06. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ANI Pharmaceuticals Inc’s profitability.
ANI Pharmaceuticals Inc stock is trading at a EV to sales ratio of 3.3373 and a EV to EBITDA ratio of -187.4829. Its price to sales ratio in the trailing 12-months stood at 2.4194.
ANI Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $739.11 million
- Total Liabilities
- $81.63 million
- Operating Cash Flow
- Capital Expenditure
- $2.24 million
- Dividend Payout Ratio
ANI Pharmaceuticals Inc ended 2023 with $739.11 million in total assets and $0 in total liabilities. Its intangible assets were valued at $739.11 million while shareholder equity stood at $311.83 million.
ANI Pharmaceuticals Inc ended 2023 with $700000.00 in deferred long-term liabilities, $81.63 million in other current liabilities, 1000.00 in common stock, $-92636000.00 in retained earnings and $28.22 million in goodwill. Its cash balance stood at $56.28 million and cash and short-term investments were $56.28 million. The company’s total short-term debt was $850,000 while long-term debt stood at $285.88 million.
ANI Pharmaceuticals Inc’s total current assets stands at $309.38 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $140.43 million compared to accounts payable of $18.99 million and inventory worth $95.89 million.
In 2023, ANI Pharmaceuticals Inc's operating cash flow was $-9814000.00 while its capital expenditure stood at $2.24 million.
Comparatively, ANI Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
ANI Pharmaceuticals Inc stock is currently trading at $39.53 per share. It touched a 52-week high of $45.99 and a 52-week low of $45.99. Analysts tracking the stock have a 12-month average target price of $46.6.
Its 50-day moving average was $42.31 and 200-day moving average was $37.25 The short ratio stood at 6.16 indicating a short percent outstanding of 0%.
Around 1311.1% of the company’s stock are held by insiders while 7483.6% are held by institutions.
Frequently Asked Questions About ANI Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.